Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

A trifecta of newly inked tech partnerships—from Eli Lilly, Bristol Myers Squibb and Incyte—exemplify the increasingly central role that AI is playing in drug development.